Compare · ORKA vs VNRX
ORKA vs VNRX
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.07B, about 860.6x VNRX ($7.0M).
- ORKA has been more active in the news (15 items in the past 4 weeks vs 10 for VNRX).
- ORKA has more recent analyst coverage (11 ratings vs 4 for VNRX).
- Company
- Oruka Therapeutics Inc.
- VolitionRX Limited
- Price
- $91.88-0.18%
- $0.38-1.67%
- Market cap
- $6.07B
- $7.0M
- 1M return
- -6.33%
- -
- 1Y return
- +493.54%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2015
- News (4w)
- 15
- 10
- Recent ratings
- 11
- 4
VNRX
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest ORKA
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $459,101 worth of shares (5,000 units at $91.82) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Klein Lawrence Otto exercised 75,000 shares at a strike of $7.80 and sold $6,887,484 worth of shares (75,000 units at $91.83) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form EFFECT filed by Oruka Therapeutics Inc.
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
Latest VNRX
- VolitionRX Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- SEC Form S-3 filed by VolitionRX Limited
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- SEC Form S-8 filed by VolitionRX Limited
- SEC Form 10-Q filed by VolitionRX Limited
- VolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
- Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
- VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update